Breaking Advances
Cancer Res August 15 2016 76 (16) 4593-4594;
These results show how MYC drives the production of specific eicosanoids critical for lung cancer cell survival and proliferation, with possible implications for the use of COX and LOX pathway inhibitors for lung cancer therapy.
This study describes a new method for cancer diagnosis based on molecular pathology, offering equivalence to histopathology as described for improved accuracy.
Poor adherence to preclinical design and reporting guidelines, coupled with publication bias, threatens the reproducibility of preclinical research of candidate therapeutics, potentially overestimating their clinical utility.
Novel microscopic methods reveal topographical deformations in oral epithelial atypia that can distinguish precursor lesions from normal/benign mucosa.
ICOS+-activated Treg accumulate in follicular lymphoma tissues and inhibit not only conventional T cells but also follicular lymphoma B cells, suggesting that anti-ICOS immunotherapy could be efficacious in this disease setting.
These findings offer a preclinical proof of concept for a more effective use of cancer stem-like cell–targeting dendritic cell vaccines in the adjuvant setting, that is, after excision of a primary tumor whose presence enforces immunosuppression.
These findings suggest cautions in the use of T cell–recruiting bispecific antibodies for the treatment of solid tumors, but also reveal that immune checkpoint-blocking antibodies can synergize powerfully with radiation to cure even very large tumors.
These findings offer a preclinical proof of concept for use of the experimental sepsis drug eritoran as a cancer therapeutic to manipulate host-microbial interactions and to improve the management of colorectal cancer.
These findings elucidate how aberrant lipid metabolism pathways sustain breast cancer cell growth, deepening the evidence that targeting these pathways may be therapeutically useful.
These findings offer a mechanistic rationale to attack aggressive brain cancers by reprogramming a critical metabolic pathway that sustains them.
This whole exome sequencing study of penile cancer, which is rare in developed countries but a significant burden in developing countries, offers the first comprehensive analysis of somatic genetic alterations in this malignancy.
In revealing an important mechanism of Notch1 stability, the results of this study could offer a therapeutic strategy to block Notch1-dependent progression in many types of cancer.
Targeted delivery of miR-196b, a tumor suppressor microRNA, may have preventive or therapeutic utility for the management of lung cancer.
mTORC2 inhibition may offer a promising therapeutic strategy to help eradicate HER2-amplified breast cancers, especially in those cases where Akt signaling is activated or tumors are resistant HER2 targeted therapy.
A multiregion sequencing approach reveals the diverse genetic events underlying intratumoral heterogeneity over the course of early metastatic melanoma, with possible implications for exploiting the mutational spectrum across multiple tumor specimens as a more reliable prognostic indicator.
Low-dose chemotherapy may be more useful than traditional doses to block the metastatic progression of certain poorly managed tumors such as cholangiocarcinoma, an aggressive and poorly managed cancer of the liver bile duct.
High intratumoral expression of squalene monooxygenase, the second rate-limiting enzyme of cholesterol synthesis, is found to be associated with a high risk of lethality in prostate cancer patients.
These results suggest a new strategy to attenuate lung cancer progression by targeting the interaction of a new suppressor of p14/ARF function with potentially special relevance to treat cancers, which arise in heavy smokers.
These results offer a preclinical proof of concept for the use of small molecules that block trimerization of PRL phosphatases, a little explored class of important cancer target molecules.
These findings offer preclinical proof of concept for a combination strategy to selectively increase the cytotoxicity of mTORC1 inhibitors, which have performed poorly in clinic, based on cotargeting glutathione-controlled oxidative stress pathways.
This study unravels mechanisms of cancer cell adaptation to major stress factors of the tumor microenvironment associated with increased aggressiveness.
These results provide preclinical proof of concept for an experimental drug that targets the key pathogenic contributions of angiopoietin-1 to the development of malignant stem-like myeloid cells.
This study highlights the importance of considering noncoding gene rearrangement fusions in cancer, along with the need to advance gene fusion detection technologies for characterizing the molecular features of heterogeneous cancers in this regard.
These results highlight the importance of epigenetic modulation in pancreatic cancer, based on impact on patient survival, with possible implications for therapeutic management.
These findings provide new insight into the molecular pathways that promote the development of oral cancers in response to carcinogenic agents.
Z-TMS is a potent antiviral and anticancer drug that appears to protect the liver from damage yet overcome drug resistance.
This work shows how a modifier of protein ubiquityation stabilizes its substrates, advancing understanding of its biological function and its role in cancer.
Cancer Research 75th Anniversary Commentaries